Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CC-95775
i
Other names:
CC-95775, FT-1101, FT 1101, CC 95775, CC95775, FT1101
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
BMS, Novo Nordisk
Drug class:
BET inhibitor
Related drugs:
‹
JQ-1 (27)
ABBV-744 (7)
ZEN-3694 (6)
INCB57643 (4)
BI 894999 (4)
SRA515 (3)
ABBV 075 (3)
GSK525762 (3)
GS-626510 (2)
PLX51107 (2)
DAK539 (2)
CPI-203 (1)
RG6146 (1)
ARCC-29 (0)
BET inhibitor (0)
CA2 (0)
EP31670 (0)
GSK1324726A (0)
INCB054329 (0)
JAB-8263 (0)
NHWD-870 (0)
ODM-207 (0)
OPN-2853 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
ZEN-3219 (0)
ZEN003365 (0)
GS-5829 (0)
RVX 208 (0)
BMS-986158 (0)
BMS-986378 (0)
JQ-1 (27)
ABBV-744 (7)
ZEN-3694 (6)
INCB57643 (4)
BI 894999 (4)
SRA515 (3)
ABBV 075 (3)
GSK525762 (3)
GS-626510 (2)
PLX51107 (2)
DAK539 (2)
CPI-203 (1)
RG6146 (1)
ARCC-29 (0)
BET inhibitor (0)
CA2 (0)
EP31670 (0)
GSK1324726A (0)
INCB054329 (0)
JAB-8263 (0)
NHWD-870 (0)
ODM-207 (0)
OPN-2853 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
ZEN-3219 (0)
ZEN003365 (0)
GS-5829 (0)
RVX 208 (0)
BMS-986158 (0)
BMS-986378 (0)
›
Associations
News
Trials
Filter by
Latest
almost3years
Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1b, N=24, Completed, Celgene | Active, not recruiting --> Completed
almost 3 years ago
Trial completion
|
GLI1 (GLI Family Zinc Finger 1)
|
CC-95775
over3years
Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1b, N=24, Active, not recruiting, Celgene | Trial primary completion date: Jul 2021 --> Oct 2021
over 3 years ago
Clinical • Trial primary completion date
|
GLI1 (GLI Family Zinc Finger 1)
|
CC-95775
over3years
Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1b, N=24, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting | N=40 --> 24
over 3 years ago
Clinical • Enrollment closed • Enrollment change
|
GLI1 (GLI Family Zinc Finger 1)
|
CC-95775
almost4years
Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1b, N=40, Recruiting, Celgene | Trial completion date: Jun 2023 --> Jul 2021 | Trial primary completion date: Jun 2023 --> Jul 2021
almost 4 years ago
Clinical • Trial completion date • Trial primary completion date
|
GLI1 (GLI Family Zinc Finger 1)
|
CC-95775
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login